Edition:
India

CTi Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

3.49USD
16 Jan 2018
Change (% chg)

$0.08 (+2.35%)
Prev Close
$3.41
Open
$3.48
Day's High
$3.50
Day's Low
$3.43
Volume
47,348
Avg. Vol
40,803
52-wk High
$5.55
52-wk Low
$2.46

Latest Key Developments (Source: Significant Developments)

CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement​
Wednesday, 29 Nov 2017 

Nov 28 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA CORP - ‍ON NOVEMBER 28, 2017, CTI BIOPHARMA CORP ENTERED INTO A LOAN AND SECURITY AGREEMENT​.CTI BIOPHARMA CORP - ‍PURSUANT TO AGREEMENT, LENDER HAS AGREED TO MAKE A SENIOR SECURED TERM LOAN OF UP TO $18 MILLION​.CTI BIOPHARMA CORP - ‍FIRST $16 MILLION OF TERM LOAN WAS FUNDED ON NOVEMBER 28, 2017​.  Full Article

CTI BIOPHARMA FILES FOR MIXED SHELF OF UP TO $200 MLN‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cti Biopharma Corp ::CTI BIOPHARMA CORP FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING‍​.  Full Article

CTI Biopharma reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - CTI Biopharma Corp ::CTI Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.28.CTI Biopharma Corp - ‍total revenues for q3 were $1.7 million compared to $4.4 million.  Full Article

CTI Biopharma appoints Laurent Fischer as new board chairman
Tuesday, 26 Sep 2017 

Sept 26 (Reuters) - CTI Biopharma Corp :CTI Biopharma appoints Laurent Fischer as new chairman of the board and announces management promotions.Announces promotion of David Kirske to chief financial officer and Bruce Seeley to chief operating officer of company.  Full Article

CTI Biopharma announces european medicines agency validation of Pacritinib
Friday, 14 Jul 2017 

July 13 (Reuters) - Cti Biopharma Corp :CTI Biopharma announces european medicines agency validation of pacritinib marketing authorization application for patients with myelofibrosis who have thrombocytopenia.CTI Biopharma Corp - announced that european medicines agency (ema) has validated marketing authorization application (maa) for pacritinib.Says if authorized, pacritinib would be granted a marketing license valid in all 28 eu member states.  Full Article

Stonepine Capital Management LLC reports 7.6 pct passive stake in CTI Biopharma Corp as of June 6, 2017
Thursday, 22 Jun 2017 

June 22 (Reuters) - Stonepine Capital Management LLC :Stonepine Capital Management LLC reports 7.6 percent passive stake in cti biopharma corp as of june 6, 2017 - SEC filing.  Full Article

Orbimed Advisors Llc reports 11.6 percent passive stake in CTI Biopharma Corp
Friday, 16 Jun 2017 

June 15 (Reuters) - Orbimed Advisors Llc: :Orbimed Advisors Llc reports 11.6 percent passive stake in CTI Biopharma Corp as of June 9 .  Full Article

CTI Biopharma announces proposed public offering of convertible preferred stock
Tuesday, 6 Jun 2017 

June 5 (Reuters) - Cti Biopharma Corp :CTI Biopharma announces proposed public offering of convertible preferred stock.‍Each share of series N-3 preferred stock will have a stated value of $1,000 per share​.CTI plans to use net proceeds from this offering in part to conduct pac203 clinical trial, submit new MAA for pacritinib to EMA.  Full Article

CTi Biopharma reports Q1 revenue $800,000
Thursday, 4 May 2017 

May 3 (Reuters) - CTi Biopharma Corp :CTi Biopharma reports first quarter 2017 financial results.Q1 loss per share $0.71.Q1 revenue $800,000 versus $36.5 million.CTi Biopharma Corp - As of March 31, 2017, cash and cash equivalents totaled $33.3 million, compared to $44.0 million as of December 31, 2016.  Full Article

CTI Biopharma announces license and agreement expansion with Servier to commercialize Pixuvri
Tuesday, 25 Apr 2017 

April 25 (Reuters) - Cti Biopharma Corp ::Servier and CTI biopharma expand license and collaboration agreement to develop and commercialize Pixuvri.Servier will commercialize Pixuvri in all markets except the US.Will retain rights to commercialize Pixuvri in the US.Servier will pay Co 12 million euros ($13.0 million) with potential for Co to receive eur 76 million in additional sales and regulatory milestone payments as well as royalties on net product sales.  Full Article

BRIEF-Spotlight Therapeutics Inc Says It Has Raised $7.3 Million In Equity Financing

* SPOTLIGHT THERAPEUTICS INC FILES TO SAY IT HAS RAISED $7.3 MILLION IN EQUITY FINANCING - SEC FILING​